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Cases
MSCs were cultured using a standardised protocol and reagents
in class 350 clean rooms. Doses of MSC ranged from 0.92 to
1.34  106/kg. All three recipients had received high dose steroids
prior to MSC infusions. The 1st recipient (41 yo F) received MSCs
on day55 for grade II-III skin GVHD with improvement noted
7 days later and complete resolution by day11. She is now 8
months post transplant with no conﬁrmed GVHD on minimal
immunosuppression. The 2nd recipient (31 yo M) received MSCs
on day39 and day47 for progressive grade III-IV skin, gut and
liver GVHD. ATG and etanercept were also given on day42. He
succumbed on day 54. The 3rd recipient (19 yo M) received
MSCs on day 42 for grade II-III skin GVHD with an encour-
aging initial response.
Conclusion
Preliminary studies demonstrate MSC infusion is feasible in the
treatment of steroid refractory aGVHD with encouraging initial
results. Further studies are needed to determine optimal dose,
timing and true response rate.
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Purpose: Mesenchymal stem cells (MSC) can differentiate to
several mesenchymal tissues and have been suggested to be used for
tissue repair. We explored the possibility to use MSCs to heal
chemoirradiation therapy-induced tissue toxicity.
Patients and Methods: Ten patients, median age 48 (13-64),
who had undergone allogeneic hematopoietic stem cell transplan-
tation (ASCT) were included. Seven had severe hemorrhagic cys-
titis (HC), two had pneumomediastinum and one had recurrent
perforated colon diverticulitis and peritonitis. MSC were HLA-
mismatched (n11), from haploidentical donors (n3) or siblings
(n2). Median MSC cell dose was 1.0 (range 0.7-2) x 106/kg. MSC
were infused i.v. One infusion was given to six patients, two
infusions to three and three infusions to one patient. A sensitive
nested PCR method for HLA alleles, sensitivity 10-5 - 10-6, was
used to detect residual MSC donor DNA in various tissues.
Results: Two patients with grades 4-5 HC had decreased trans-
fusion requirements after MSC infusion, but died of multi-organ
failure. In one patient, MSC donor DNA was demonstrated in the
urinary bladder. In ﬁve patients, with moderate to severe grades
2-3 HC, urine cleared after MSC infusion. In two patients, pneu-
momediastinum disappeared after MSC infusions. A patient with
steroid-resistant graft-versus-host disease of the gut experienced
perforated diverticulitis and peritonitis that was reversed twice by
MSC. Five patients died from infections and three are alive 5, 10
and 16 months after ASCT.
Conclusion: MSC is a novel therapy for therapy-induced tissue
toxicity that deserves further evaluation.
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CD4CD25 T cells (Treg) have been found to exert their affects
on multiple types of immunologically relevant cells including CD4,
CD8 and NK populations. Based upon the expanding application of
Treg cells in stem cell transplants for the control of GVHD, rejection
(HVG) and GVL responses, we hypothesized that following T cell
receptor engagement and activation in recipients, CD4CD25 cells
may modulate hematopoietic responses via production of effector
cytokines. Various populations of CD4CD25 T cells were there-
fore initially co-cultured with unfractionated syngeneic bone marrow
cells (BMC) for 24 hr. Following co-culture, cells were collected and
replated together with hematopoietic growth factors and and CFU
numbers assessed. CD4CD25 T cells were puriﬁed from BALB/c
or B6-CD8-/- mice which were then activated for 3-8 days with
anti-CD3/CD28 beads. These cells inhibited syngeneic CFU-IL3 or
CFU-HPP (multi-potential progenitors) colony formation at low
ratios of CD4CD25: BMC. Notably, Tregs from B6-CD8-/- mice
exhibited comparable inhibition of allogeneic (BALB/c) CFU-IL3.
Non-activated CD4CD25 T cells co-cultured with BMC did not
exhibit this inhibitory. Contact dependency was found to be required
for this effect as separation of activated CD4CD25 T cells from
BMC targets in trans-well cultures abrogated inhibition. Prior deple-
tion of CD25 cells in vivo resulted in increases in CFU-GM 7-9 days
after syngeneic BMT in mice suggesting that Tregs can inhibit he-
matopoietic reconstitution in vivo. TGF	 is known to inhibit prolif-
eration by hematopoietic PC. TGF	 expression was detected by
western analysis in lysates of Treg cell populations correlating with
their ability to inhibit PC responses. To examine a potential contri-
bution of TGF	 in this model, neutralizing anti-TGF	 mab was
added during Treg cell  BMC co-culture. The inhibition of CFU
activity was abrogated in the presence of this antibody. To begin
investigating the role of MHC class II molecules in this Treg cell
activity, c-kit enriched (85%) BMC from B6-MHC class II KO
and B6-wt mice were co-cultured with B6 Treg. In contrast to B6-wt
BMC, CFU inhibition was not detected against the MHC class II
deﬁcient BMC. In summary, this is the ﬁrst report demonstrating that
CD4CD25 T cells can alter hematopoietic PC activity. We hy-
pothesize that membrane bound TGF	 may participate in effecting
such regulation via direct Treg cell interactions with PC populations.
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The signiﬁcant role of direct contact between hematopoietic
progenitor cells (HPC) and the cellular microenvironment for
maintaining “stemness” has been demonstrated. Human mesen-
chymal stromal cell (MSC) feeder layers represent a surrogate
model for this interaction. To deﬁne this cell-cell contact between
HPC and MSC, we have studied adhesive interaction of various
fractions of HPC with different preparations of MSC by using a
novel assay based on gravitational force upon inversion. Adherent
and non-adherent cells were separated and further investigated by
microarray analysis (GeneChip Human Genome U133_Plus_2.0,
Affymetrix) and long-term hematopoietic culture initiating cell
(LTC-IC) frequency. HPC subsets with higher self-renewing ca-
pacity demonstrated signiﬁcantly higher adherence to MSC from
human bone marrow (CD34 vs. CD34-, CD34/CD38- vs.
CD34/CD38, slow dividing fraction vs. fast dividing fraction).
The fraction of CD34 cells that were adherent to MSC were
separated from those that were non-adherent. LTC-IC frequency
was signiﬁcantly higher in the adherent fraction. Genes coding for
adhesion proteins and extracellular matrix were higher expressed in
the adherent fraction compared to non-adherent CD34 cells.
Furthermore, afﬁnity of CD34 cells was analyzed on human
MSC isolated from bone marrow (BM), adipose tissue (AT) and
cord blood (CB). Afﬁnity to BM-MSC was signiﬁcantly higher
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compared to AT- and CB-MSC. We have analyzed the molecular
proﬁle of BM-MSC, AT-MSC and CB-MSC. Gene expressions in
BM-MSC preparations correlated with their potential for driving
HPC into self-renewal. Following genes were up-regulated: cad-
herin11, N-cadherin, ITGA1, ITGA5 and ITGB1, VCAM1, pro-
tocadherin18, SDF-1. Western blot analysis also conﬁrmed higher
protein expression of ITGB1, FN1, cadherin11 and N-cadherin in
BM-MSC compared to AT-MSC and CB-MSC.
BM-MSC therefore represent a surrogate model for the human
hematopoietic niche. Primitive subsets of HPC demonstrated a
high afﬁnity to BM-MSC compared to more differentiated frac-
tions. This correlated with the expression of cadherin 11, N-
cadherin and 	1 integrins.
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Hematopoietic cell transplantation (HCT) is a life-saving ther-
apy for many patients with leukemia, lymphoma, and breast cancer.
However, it is not known how many, and to what extent, survivors
participate in healthy behaviors and recommended preventive ser-
vices to avoid future health problems after transplant. We collected
self-reported information on health-preserving behaviors as part of
a large, cross-sectional study of long-term HCT survivors, spouses,
and acquaintances. Information on both health provider indepen-
dent (behaviors that do not require medical contact, i.e., tobacco
and alcohol avoidance, exercise) and health provider dependent
(e.g., cholesterol test, blood pressure check, sigmoidoscopy, skin
exam, breast exam, mammogram, immunizations) practices was
obtained through telephone interviews. Participants included 662
HCT survivors (41% allogeneic and 59% autologous) recruited
from 40 North American transplant centers, 177 spouses, 158
controls matched to survivors on sex, age, martial status, and
education level. 238 (36%) of HCT survivors had had acute leu-
kemia, 128 (20%) CML, 131 (20%) lymphoma, and 154 (23%)
breast cancer. Survivors were predominately Caucasian (92%),
married (73%), female (62%), and well-educated (71% had post
high school education). Mean age was 49 yrs (SD10; range 21-77
yrs) and mean time since HCT was 7 yrs (SD 3; range 2-23 yrs).
84% of survivors reported that they never smoke, 59% never drink
alcohol, and 35% often/always exercise at least 20 minutes/day 3
times/week. Despite 94% of survivors reporting they had a physi-
cian and 92% having health insurance coverage, only 56% of
survivors reported having received a ﬂu shot in the last year.
Although allogeneic survivors were more likely than autologous
survivors to report having had a skin exam in the past year (54% vs.
43%, p.002), those rates were low given their vulnerability to
skin cancer. Additional comparisons between type of transplant, as
well as time since transplant and cohort group (survivors, spouses,
matched controls) are underway. Overall self-reported compliance
with recommended health behaviors in HCT survivors was rea-
sonably good compared to the general population, but there re-
mains considerable room for improvement. Survivors’ frequent
contact with the medical system and past experience with illness
provide opportunities to improve prevention screening and to
promote healthy behaviors in HCT survivors and their families.
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FA is an autosomal recessive disorder characterized by progres-
sive bone marrow failure, congenital abnormalities and a predis-
position to malignancies. SCT is the only treatment that can
restore normal hematopoiesis but long term follow up(LTFU) is
essential especially because of the high incidence of cancer in
these pts. From 1983 to 2006, 168pts were transplanted in our
BMT Unit. In this study we evaluated the outcome of 43 pts
transplanted between 1983-1996 from related bone marrow
compatible donors. Aplastic phase:40pts, MDS/Leukemia:3pts.
No radiotherapy was given in the preparatory regimen. 36/43pts
survived 28d and were evaluable for engraftment. 34 had a
sustained hematological engraftment and 2pts had a partial
engraftment. One pt with previous MDS relapsed and died after
a 2nd BMT. No other pt rejected their graft. 19pts died between
1-3101d after SCT(M:48d) due to infections or
hemorrhage(13pts), tongue carcinoma(2pts) and extensive C-
GVHD/ infections (5pts). Twenty-four pts are alive between
10-18,3years after BMT(M:12,4years). Median age was 8y(3-32)
at SCT and 20,5y(13-47) at most recent evaluation.Gender:9F/
15M. Aplastic phase: all pts. Preparatory regimen: CY200: 3pts;
CY140ATG:8pts; CY120:4pts; Cy100:9pts. GVHD prophy-
laxis: cyclosporine (Csa)MTX: 20pts; Csa  steroids:4pts.
Mucositis grade II-IV occurred in 19pts and severe hemorrhage
in 5pts. A-GVHD grade II-III: 2pts. Extensive C-GVHD:
2pts.Chimerism was evaluated by VNTR analysis in 21 pts and
by cytogenetics or blood type in 3 pts. All pts have normal blood
counts and only 3 pts had a mixed chimerism (80-90% of
donor’s cells). One pt developed esophagus stenosis after SCT
due to severe mucositis. 18pts were transplanted before the age
of 12y and only 2pts(female/male) needed hormonal replace-
ment to enter puberty. Reproductive function: Only 2pts be-
came pregnant 6y and 11 y after SCT. One of them delivered a
healthy child and the other had a spontaneous abortion. Hypo-
thyreoidism was detected in 2pts. Malignancies developed in
2/24pts (basal cell carcinoma and tongue carcinoma). Alto-
gether, 3/43pts developed tongue carcinoma. All of them had
grade IV mucositis and only one had severe acute and chronic
GVHD. Conclusion: FA pts treated with SCT should be care-
fully monitored for life time in order to detect cancer and other
complications.
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The capacity to assess environmental inputs to biological
phenotypes is limited by methods that can accurately and quan-
titatively measure these contributions. One such example can be
seen in the context of exposure to ionizing radiation. The
purposeful detonation of radiological or nuclear materials by
terrorists has been recognized as a major threat to U.S. national
security. Unfortunately, no rapid or practical assays are available
to measure internal biodosimetry in a large population of af-
fected individuals. To address this problem, we have made use
of gene expression analysis of peripheral blood mononuclear
cells (PB MNCs) to develop expression proﬁles that accurately
reﬂect prior radiation exposure. Importantly, we demonstrate
that expression proﬁles can be developed that not only predict
radiation exposure in mice but also distinguish the level of
radiation exposure, ranging from 50 cGy to 1000 cGy. Likewise,
a molecular signature of radiation response developed solely
from analysis of peripheral blood samples from irradiated stem
cell transplant patients can predict and distinguish irradiated
human PB samples from non-irradiated samples with an accu-
racy of 90%, sensitivity of 85% and speciﬁcity of 94%. We
further demonstrate that a radiation proﬁle developed in the
mouse can correctly distinguish PB samples from irradiated and
non-irradiated human patients with an accuracy of 77%, sensi-
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